tb drug discovery
lilly tb drug
working with us
approach to IP
The first step to treating or curing a disease is quickly and accurately diagnosing it. The development of diagnostics for some of the world's most neglected, but burdensome infectious diseases is an important part of IDRI’s research activities. The common goal of our diagnostics programs is to enable ready access to low-cost diagnostic products that are easy to use and stable for long periods despite the extreme environmental conditions characteristic of endemic regions. The diagnostic products should also provide a rapid readout suitable for use at the point of care or in a regional clinic.
Our current focus is the development of tests for antibody detection. Antibodies are proteins produced by the body's immune system against specific foreign molecules of invading bacteria and viruses. The function of these antibodies is to neutralize these pathogenic organisms, and for this to happen successfully they must bind very specifically with the pathogen molecules. The presence of specific antibodies within a person indicates that he or she has been infected by one of these pathogens.
Detecting these pathogen-specific antibodies as early as possible is critical for determining the most appropriate treatment regimen. Along with our manufacturing partners, we have shown through extensive testing that antibody-detection tests can be produced that are: highly specific to targeted antibodies, highly sensitive in order to identify infection early and low cost.
As a notprofit organization, we are able to supply our commercial partners with the inexpensive, high-quality, and unique molecules that are critically important to the manufacture and marketing of low-cost and accurate diagnostic tests. Currently, our reagents are available for license against visceral leishmaniasis, leprosy and Chagas disease. Diagnostic products using these reagents are already being used in several countries.